A Phase 2 interventional study of encorafenib and Binimetinib in BRAF V600E-mutant Metastatic Colorectal Cancer, sponsored by Pierre Fabre Medicament. Completed at 45 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing encorafenib in Colorectal Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. encorafenib · Colorectal Neoplasms.
Among the 16 studies testing encorafenib in Colorectal Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 5th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →5 of the 16 studies testing encorafenib in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Vall d'Hebron Institute of Oncology · Sites in Spain
Ages 18+
Federation Francophone de Cancerologie Digestive · Sites in France
Ages 18+
Oslo University Hospital · Sites in Norway
Ages 18+
By country, each count listing its studies:
encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 2
First in 2011; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 95 across the 16 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Medicament, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Medicament is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
Pierre Fabre has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing encorafenib in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
| NCT06411600Vall d'Hebron Institute of OncologyCombination Therapy for BRAF-V600E Metastatic CRCm | 2027-05-01 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing encorafenib in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in subjects with mCRC. The preclinical results and preliminary clinical data together justify the evaluation of this triple combination in the first-line setting of this population. The primary objective of the study is to evaluate the antitumor activity of the combination of encorafenib, binimetinib and cetuximab by assessing the overall response rate in adult subjects with previously untreated BRAFV600E-mutant metastatic colorectal cancer. It will also assess the effect of the triple combination on the duration of response, time to response, progression-free survival and overall survival and assess the effect on quality of life. It will also characterize the safety and tolerability of the triple combination as well as describe the pharmacokinetics (PK) of encorafenib, binimetinib, and cetuximab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
encorafenib plus binimetinib plus cetuximab
Drug: encorafenib · Drug: Binimetinib · Drug: Cetuximab
300 mg administered orally once daily (QD)
Also known as: Braftovi
Binimetinib 45 mg administered orally twice daily (BID)
Also known as: Mektovi
Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) : (\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward. Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic.
Also known as: Erbitux
Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments
The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months.
Confirmed Overall Response Rate (cORR) Based on Central Tumor Assessment
The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months
Overall Response Rate (ORR) Based on Local Tumor Assessments
The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months
Overall Response Rate (ORR) Based on Central Tumor Assessments
The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
Time frame: From initiation of treatment to disease progression up to a maximum of 17.6 months
Duration of Response (DOR) Per Local Assessment
Time from first radiographic evidence of response based on local radiologist/investigator review to the earliest documented PD or death due to underlying disease
Time frame: From first radiographic evidence of response to disease progression up to a maximum of 17.6 months
Duration of Response (DOR) Per Central Assessment
Time from first radiographic evidence of response based on central review to the earliest documented PD or death due to underlying disease
Time frame: From first radiographic evidence of response to disease progression up to a maximum of 17.6 months
Time to Response (TTR) Per Local Review
The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per local review
Time frame: From initiation of treatment to the first radiographic evidence of response up to a maximum of 17.6 months
Time to Response (TTR) Per Central Review
The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per central review
Time frame: From initiation of treatment to the first radiographic evidence of response up to a maximum of 17.6 months
Progression-Free Survival (PFS) Per Local Review
Time from first dose to the earliest documented date of disease progression based on local radiologist/investigator review or death due to any cause
Time frame: From initiation of treatment to disease progression or death up to a maximum of 17.6 months
Progression of Free Survival (PFS) Per Central Review
Time from first dose to the earliest documented date of disease progression based on central review or death due to any cause
Time frame: From initiation of treatment to disease progression or death up to a maximum of 17.6 months
Overall Survival (OS)
Time from first dose to death due to any cause
Time frame: From initiation of treatment to death up to a maximum of 17.6 months
Change From Baseline in EORTC QLQ-C30 Over Time
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for cancer subjects (EORTC QLQ-C30) includes a global health status/QoL. The scale ranges in score from 0 to 100, higher score on the global health status/QoL scale indicate higher QoL. Changes from baseline in EORTC QLQ-C30 global health status/quality of life (QoL) over time are presented in this record.
Time frame: From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months
Change From Baseline in EQ-5D-5L Over Time
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L VAS records the patient's self-rated health on a vertical visual analogue scale numbered from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). Changes from baseline in EQ-5D-5L VAS over time are presented in this record.
Time frame: From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months
PGIC Scores Over Time
The Patient Global Impression of Change (PGIC) is a measure of patients' perceptions of change in their symptoms over time. For this assessment, subjects answered the following question: "Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse."
Time frame: From Cycle 1 Day 1 (C1D1) Visit to the 30-day Safety Follow-up Visit up to a maximum of 17.6 months
95 subjects were enrolled in the study between 17 January 2019 and 27 December 2019 in 68 investigational centers : 45 in EU, 7 in UK, 10 in USA and 6 in Japan
| Milestone | Encorafenib Plus Binimetinib Plus Cetuximab |
|---|---|
| Started | 95 |
| Completed | 20 |
| Not completed | 75 |
| Withdrew: Disease progression | 48 |
| Withdrew: Adverse event | 16 |
| Withdrew: Physician decision | 6 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Death | 1 |
| Withdrew: Non compliance with study drug | 1 |
| Withdrew: Withdrawal by subject | 1 |
The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
| percentage of confirmed responses | 1 Arm |
|---|---|
| Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments | 47.8 (37.3 to 58.5) |
The confirmed overall response rate (cORR) is the percentage of confirmed responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
| percentage of confirmed responses | 1 Arm |
|---|---|
| Confirmed Overall Response Rate (cORR) Based on Central Tumor Assessment | 45.7 (35.2 to 56.4) |
The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by local radiologist/investigator review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
| percentage of responses | 1 Arm |
|---|---|
| Overall Response Rate (ORR) Based on Local Tumor Assessments | 62 (51.2 to 71.9) |
The overall response rate (ORR) is the percentage of responses, defined as complete response (CR) or partial response (PR), as assessed by central radiologist review based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions; Partiel response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.
| percentage of responses | 1 Arm |
|---|---|
| Overall Response Rate (ORR) Based on Central Tumor Assessments | 60.9 (50.1 to 70.9) |
Time from first radiographic evidence of response based on local radiologist/investigator review to the earliest documented PD or death due to underlying disease
| months | 1 Arm |
|---|---|
| Duration of Response (DOR) Per Local Assessment | 5.1 (3.7 to 6.9) |
Time from first radiographic evidence of response based on central review to the earliest documented PD or death due to underlying disease
| months | 1 Arm |
|---|---|
| Duration of Response (DOR) Per Central Assessment | 5.1 (3.4 to 5.5) |
The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per local review
| months | 1 Arm |
|---|---|
| Time to Response (TTR) Per Local Review | 1.4 (1.4 to 1.5) |
The TTR is defined as the time from the first dose until the first documented radiographic evidence of response of CR or PR per central review
| months | 1 Arm |
|---|---|
| Time to Response (TTR) Per Central Review | 1.4 (1.3 to 1.4) |
Time from first dose to the earliest documented date of disease progression based on local radiologist/investigator review or death due to any cause
| months | 1 Arm |
|---|---|
| Progression-Free Survival (PFS) Per Local Review | 5.8 (4.6 to 6.4) |
Time from first dose to the earliest documented date of disease progression based on central review or death due to any cause
| months | 1 Arm |
|---|---|
| Progression of Free Survival (PFS) Per Central Review | 5.0 (4.6 to 6.4) |
Time from first dose to death due to any cause
| months | 1 Arm |
|---|---|
| Overall Survival (OS) | 17.2 (14.1 to NA) |
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for cancer subjects (EORTC QLQ-C30) includes a global health status/QoL. The scale ranges in score from 0 to 100, higher score on the global health status/QoL scale indicate higher QoL. Changes from baseline in EORTC QLQ-C30 global health status/quality of life (QoL) over time are presented in this record.
| units on a scale | 1 Arm |
|---|---|
| C2D1 | -2.64 ± 19.270 |
| C3D1 | -0.35 ± 20.866 |
| C4D1 | 0.97 ± 20.238 |
| C5D1 | -0.89 ± 18.026 |
| C6D1 | -1.92 ± 22.544 |
| C7D1 | -5.39 ± 22.834 |
| C8D1 | -4.63 ± 21.225 |
| C9D1 | -1.85 ± 15.274 |
| C10D1 | -7.69 ± 17.167 |
| 30 days safety Follow up | -15.42 ± 25.775 |
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L VAS records the patient's self-rated health on a vertical visual analogue scale numbered from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). Changes from baseline in EQ-5D-5L VAS over time are presented in this record.
| units on a scale | 1 Arm |
|---|---|
| C2D1 | 0.04 ± 19.707 |
| C3D1 | 0.35 ± 21.668 |
| C4D1 | 2.66 ± 19.400 |
| C5D1 | 3.73 ± 17.052 |
| C6D1 | 1.69 ± 18.421 |
| C7D1 | 1.31 ± 18.903 |
| C8D1 | 2.89 ± 15.882 |
| C9D1 | -2.32 ± 21.945 |
| C10D1 | -4.00 ± 12.503 |
| 30 days safety Follow up | -9.35 ± 23.585 |
The Patient Global Impression of Change (PGIC) is a measure of patients' perceptions of change in their symptoms over time. For this assessment, subjects answered the following question: "Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse."
| Participants | 1 Arm |
|---|---|
| C2D1 — Very much improved | 5 |
| C2D1 — Much improved | 15 |
| C2D1 — Minimally improved | 17 |
| C2D1 — No change | 29 |
| C2D1 — Minimally worse | 3 |
| C2D1 — Much worse | 0 |
| C2D1 — Very much worse | 0 |
| C2D1 — Missing, not done | 22 |
| C3D1 — Very much improved | 10 |
| C3D1 — Much improved | 28 |
| C3D1 — Minimally improved | 11 |
| C3D1 — No change | 20 |
| C3D1 — Minimally worse | 0 |
| C3D1 — Much worse | 0 |
| C3D1 — Very much worse | 0 |
| C3D1 — Missing, not done | 12 |
| C4D1 — Very much improved | 9 |
| C4D1 — Much improved | 31 |
| C4D1 — Minimally improved | 12 |
| C4D1 — No change | 16 |
| C4D1 — Minimally worse | 0 |
| C4D1 — Much worse | 0 |
| C4D1 — Very much worse | 0 |
| C4D1 — Missing, not done | 9 |
| C5D1 — Very much improved | 10 |
| C5D1 — Much improved | 19 |
| C5D1 — Minimally improved | 11 |
| C5D1 — No change | 13 |
| C5D1 — Minimally worse | 2 |
| C5D1 — Much worse | 0 |
| C5D1 — Very much worse | 0 |
| C5D1 — Missing, not done | 10 |
| C6D1 — Very much improved | 7 |
| C6D1 — Much improved | 18 |
| C6D1 — Minimally improved | 13 |
| C6D1 — No change | 13 |
| C6D1 — Minimally worse | 0 |
| C6D1 — Much worse | 0 |
| C6D1 — Very much worse | 0 |
| C6D1 — Missing, not done | 6 |
| C7D1 — Very much improved | 4 |
| C7D1 — Much improved | 13 |
| C7D1 — Minimally improved | 7 |
| C7D1 — No change | 11 |
| C7D1 — Minimally worse | 0 |
| C7D1 — Much worse | 0 |
| C7D1 — Very much worse | 0 |
| C7D1 — Missing, not done | 8 |
| C8D1 — Very much improved | 4 |
| C8D1 — Much improved | 11 |
| C8D1 — Minimally improved | 5 |
| C8D1 — No change | 5 |
| C8D1 — Minimally worse | 2 |
| C8D1 — Much worse | 0 |
| C8D1 — Very much worse | 0 |
| C8D1 — Missing, not done | 6 |
| C9D1 — Very much improved | 1 |
| C9D1 — Much improved | 9 |
| C9D1 — Minimally improved | 2 |
| C9D1 — No change | 5 |
| C9D1 — Minimally worse | 0 |
| C9D1 — Much worse | 0 |
| C9D1 — Very much worse | 0 |
| C9D1 — Missing, not done | 3 |
| C10D1 — Very much improved | 2 |
| C10D1 — Much improved | 4 |
| C10D1 — Minimally improved | 4 |
| C10D1 — No change | 4 |
| C10D1 — Minimally worse | 0 |
| C10D1 — Much worse | 0 |
| C10D1 — Very much worse | 0 |
| C10D1 — Missing, not done | 0 |
| 30 days safety Follow-up — Very much improved | 3 |
| 30 days safety Follow-up — Much improved | 12 |
| 30 days safety Follow-up — Minimally improved | 5 |
| 30 days safety Follow-up — No change | 9 |
| 30 days safety Follow-up — Minimally worse | 6 |
| 30 days safety Follow-up — Much worse | 6 |
| 30 days safety Follow-up — Very much worse | 0 |
| 30 days safety Follow-up — Missing, not done | 31 |
Collected over From patient enrolment date to 30 days after the last dose of study drug up to a maximum of 17.6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 Arm | 27/95 (28.4%) | 49/95 (51.6%) | 93/95 (97.9%) |
| Event | 1 Arm |
|---|---|
| Large intestinal obstructionGastrointestinal disorders | 6/95 |
| Acute kidney injuryRenal and urinary disorders | 6/95 |
| Intestinal obstructionGastrointestinal disorders | 5/95 |
| NauseaGastrointestinal disorders | 5/95 |
| Abdominal painGastrointestinal disorders | 4/95 |
| DiarrhoeaGastrointestinal disorders | 4/95 |
| Small intestinal obstructionGastrointestinal disorders | 4/95 |
| VomitingGastrointestinal disorders | 4/95 |
| AnaemiaBlood and lymphatic system disorders | 2/95 |
| PyrexiaGeneral disorders and administration site conditions | 2/95 |
| Event | 1 Arm |
|---|---|
| DiarrhoeaGastrointestinal disorders | 64/95 |
| NauseaGastrointestinal disorders | 42/95 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 38/95 |
| RashSkin and subcutaneous tissue disorders | 38/95 |
| VomitingGastrointestinal disorders | 34/95 |
| Abdominal painGastrointestinal disorders | 31/95 |
| AstheniaGeneral disorders and administration site conditions | 30/95 |
| Dry skinSkin and subcutaneous tissue disorders | 30/95 |
| ConstipationGastrointestinal disorders | 25/95 |
| AnaemiaBlood and lymphatic system disorders | 23/95 |
| Age, Categorical(Participants) | 1 Arm |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 43 |
| >=65 years | 52 |
| Age, Continuous(years) | 1 Arm |
|---|---|
| Median | 65 (57 to 70) |
| Sex: Female, Male(Participants) | 1 Arm |
|---|---|
| Female | 51 |
| Male | 44 |
| Ethnicity (NIH/OMB)(Participants) | 1 Arm |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 73 |
| Unknown or Not Reported | 14 |
| Race (NIH/OMB)(Participants) | 1 Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 71 |
| More than one race | 0 |
| Unknown or Not Reported | 13 |
| Region of Enrollment(Participants) | 1 Arm |
|---|---|
| Austria | 1 |
| Netherlands | 1 |
| Belgium | 9 |
| United States | 3 |
| Japan | 11 |
| Italy | 15 |
| United Kingdom | 13 |
| France | 13 |
| Spain | 29 |
| Primary tumor location(Participants) | 1 Arm |
|---|---|
| Right-sided/transverse | 57 |
| Left-sided/rectum | 37 |
| Other | 1 |
| Number of metastatic organs(Participants) | 1 Arm |
|---|---|
| 1 | 23 |
| 2 | 33 |
| >2 | 39 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Jun 2020, 17 months.
Results were first posted in Aug 2022, 2 years 2 months after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 17 months is below that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Encorafenib · Binimetinib · Cetuximab